New physiologic lessons highlight the role of intestine hormones in contributing to insulin resistance. Fractyl has developed a device-based endoscopic procedure to directly address this intestinal hormonal impairment using an outpatient therapy. Fractyl is currently engaged in clinical trials designed to demonstrate that its endoscopic procedure can dramatically improve glucose control and potentially reduce the need for additional medications. The company's mission is to set people free from the daily burdens of type 2 diabetes management, empower physicians with a safe and reliable therapeutic treatment option, and lower the tremendous human and financial costs of diabetic complications for patients, hospitals, and payers.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/04/14	$40,000,000	Series C	Domain Associates	undisclosed
11/30/17	$44,000,000	Series D	Deerfield Management Company, L.P. Domain Associates Emergent Medical Partners IDO Fund Mithril Capital Management True Ventures	undisclosed
08/06/20	$55,000,000	Series E	Catalio Capital Management CDIB Venture Capital Domain Associates Emergent Medical Partners GV Mithril Capital Management Taiwania Capital Management Corporation True Ventures YJ Capital	undisclosed